Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, April 1, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS, TSX: AEZ) (the \"Company\") today announced that a poster will be\n presented on AEZS-134, a highly potent and selective ATP competitive\n Erk inhibitor, during the American Association for Cancer Research\n (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego,\n California.\n\n\n\n\n\n\n\nAbstract #3711:\n\n\n\"Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and\n Mek- Inhibitor Resistant Tumors\", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T.\n Schuster and M. Teifel.\n\n\n\n\n \n\n\n \n\n\n\n\nPresenter:\n\n\nIrene Seipelt, PhD, Director, Preclinical Development at Aeterna\n Zentaris\n\n\n\n\n \n\n\n \n\n\n\n\nPoster Session:\n\n\nExperimental and Molecular Therapeutics 26\n\n\n\n\n \n\n\n \n\n\n\n\nDate & Time:\n\n\nTuesday, April 8, 2014, 8 am-12 pm (Pacific time)\n\n\n\n\n \n\n\n \n\n\n\n\nVenue:\n\n\nHall A-E, poster section 31, San Diego Convention Center\n\n\n\n\n\n\n\nAbout AEZS-134\n\n\nAEZS-134 is an integral part of the Company's kinase research program\n comprising the investigation of different compounds for single Erk\n inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition.\n AEZS-134 selectively inhibits the kinase activity of Erk. AEZS-134 was\n discovered using the Company's proprietary compound library and high\n throughput screening technology. AEZS-134 is available for partnering.\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a specialty biopharmaceutical company engaged in\n developing novel treatments in oncology and endocrinology. The\n Company's pipeline encompasses compounds at various stages of\n development. For more information, visit www.aezsinc.com.\n\n\nSOURCE Aeterna Zentaris Inc.\n\n\n\n Paul Burroughs Director of Communications (418) 652-8525 ext. 406 [email protected] Copyright CNW Group 2014","length":3056,"tagName":"div"}]

More updates from Cosciens Biopharma Inc.